243 related articles for article (PubMed ID: 9705597)
1. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
Rutgeerts P
Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
[TBL] [Abstract][Full Text] [Related]
2. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
3. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
4. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
Gross V
Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
[TBL] [Abstract][Full Text] [Related]
5. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
6. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
7. Budesonide in inflammatory bowel disease.
Lamers CB; Wagtmans MJ; van der Sluys Veer A; van Hogezand RA; Griffioen G
Neth J Med; 1996 Feb; 48(2):60-3. PubMed ID: 8819801
[TBL] [Abstract][Full Text] [Related]
8. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
9. [Local or systemic treatment of inflammatory bowel diseases?].
Schmassmann A; Halter F
Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
[TBL] [Abstract][Full Text] [Related]
10. [Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
Vermeire S; Rutgeerts P
Zentralbl Chir; 1998; 123(4):352-6. PubMed ID: 9622893
[TBL] [Abstract][Full Text] [Related]
11. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
[TBL] [Abstract][Full Text] [Related]
12. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
[TBL] [Abstract][Full Text] [Related]
13. Budesonide in the treatment of inflammatory bowel disease.
Silverman J; Otley A
Expert Rev Clin Immunol; 2011 Jul; 7(4):419-28. PubMed ID: 21790284
[TBL] [Abstract][Full Text] [Related]
14. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid-sparing treatments in patients with Crohn's disease.
Plevy SE
Am J Gastroenterol; 2002 Jul; 97(7):1607-17. PubMed ID: 12135008
[TBL] [Abstract][Full Text] [Related]
16. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
[TBL] [Abstract][Full Text] [Related]
17. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
19. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible?
Rutgeerts P
Neth J Med; 1994 Aug; 45(2):60-4. PubMed ID: 7936007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
